Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Strongbridge Bio Ord (SBBP)

Strongbridge Bio Ord (SBBP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 135,658
  • Shares Outstanding, K 67,829
  • Annual Sales, $ 30,730 K
  • Annual Income, $ -45,080 K
  • 60-Month Beta 1.59
  • Price/Sales 4.35
  • Price/Cash Flow N/A
  • Price/Book 3.06
Trade SBBP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.75
  • Most Recent Earnings N/A on 08/05/21
  • Next Earnings Date 11/04/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility N/A
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.95 +2.56%
on 10/05/21
2.32 -13.79%
on 09/10/21
-0.24 (-10.71%)
since 09/03/21
3-Month
1.85 +8.11%
on 08/16/21
3.19 -37.30%
on 07/06/21
-1.08 (-35.06%)
since 07/02/21
52-Week
1.85 +8.11%
on 08/16/21
4.26 -53.05%
on 02/16/21
-0.16 (-7.41%)
since 10/05/20

Most Recent Stories

More News
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”)...

SBBP : 2.00 (+1.52%)
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that the High Court of Ireland...

SBBP : 2.00 (+1.52%)
Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ:...

SBBP : 2.00 (+1.52%)
XERS : 1.96 (-9.68%)
Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that its shareholders have...

SBBP : 2.00 (+1.52%)
XERS : 1.96 (-9.68%)
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris

SBBP : 2.00 (+1.52%)
XERS : 1.96 (-9.68%)
Xeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote “FOR” the Transaction With Strongbridge Biopharma

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) today announced that a leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Xeris stockholders vote “FOR”...

SBBP : 2.00 (+1.52%)
XERS : 1.96 (-9.68%)
Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals

SBBP : 2.00 (+1.52%)
XERS : 1.96 (-9.68%)
Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update

~ Reports KEVEYIS ®  (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~

SBBP : 2.00 (+1.52%)
Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement

DUBLIN, Ireland and TREVOSE, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“ Strongbridge ”), a global commercial-stage biopharmaceutical company focused on the...

SBBP : 2.00 (+1.52%)
Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue

DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“ Strongbridge ”), a global commercial-stage biopharmaceutical company focused on the...

SBBP : 2.00 (+1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing's syndrome, COR-004 and COR-005 to treat acromegaly,...

See More

Key Turning Points

3rd Resistance Point 2.17
2nd Resistance Point 2.11
1st Resistance Point 2.06
Last Price 2.00
1st Support Level 1.95
2nd Support Level 1.89
3rd Support Level 1.84

See More

52-Week High 4.26
Fibonacci 61.8% 3.34
Fibonacci 50% 3.06
Fibonacci 38.2% 2.77
Last Price 2.00
52-Week Low 1.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar